$1.92
0.00% day before yesterday
Nasdaq, Aug 30, 01:58 am CET
ISIN
US81642T1007
Symbol
SLS

SELLAS Life Sciences Group, Inc. Stock price

$1.92
+0.23 13.61% 1M
+0.74 62.71% 6M
+0.88 84.62% YTD
+0.62 47.69% 1Y
-1.27 39.81% 3Y
-0.22 10.28% 5Y
-47,398.08 100.00% 10Y
-6.79 77.96% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
+0.00 0.00%
ISIN
US81642T1007
Symbol
SLS
Industry

Key metrics

Basic
Market capitalization
$202.2m
Enterprise Value
$176.9m
Net debt
positive
Cash
$25.3m
Shares outstanding
100.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
7.7
Financial Health
Equity Ratio
48.7%
Return on Equity
-327.5%
ROCE
-103.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | -
EBIT
$-27.2m | $-30.0m
Net Income
$-26.3m | $-34.9m
Free Cash Flow
$-31.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
21.9% | 6.3%
Net Income
23.8% | -12.6%
Free Cash Flow
8.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.3
FCF per Share
$-0.3
Short interest
28.0%
Employees
15
Rev per Employee
$0.0
Show more

Is SELLAS Life Sciences Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

SELLAS Life Sciences Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a SELLAS Life Sciences Group, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a SELLAS Life Sciences Group, Inc. forecast:

Buy
86%
Hold
14%

Financial data from SELLAS Life Sciences Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 11 11
17% 17%
-
- Research and Development Expense 16 16
25% 25%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -27 -27
22% 22%
-
Net Profit -26 -26
24% 24%
-

In millions USD.

Don't miss a Thing! We will send you all news about SELLAS Life Sciences Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SELLAS Life Sciences Group, Inc. Stock News

Positive
Seeking Alpha
13 days ago
SELLAS Life Sciences is developing GPS as a WT1 immunotherapy, which is in Phase 3 for AML. However, I believe their SLS009 candidate as a CDK9 inhibitor further gives the stock broad AML applicability. GPS's REGAL final analysis at 80 events expected should come by year-end 2025. Its prior data suggest survival advantages versus historical controls.
Neutral
GlobeNewsWire
25 days ago
-        Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events        - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Independent Data Monitoring Co...
Neutral
GlobeNewsWire
about 2 months ago
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the addition of Linghua Wang, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Wang is a widely respected leader in cance...
More SELLAS Life Sciences Group, Inc. News

Company Profile

SELLAS Life Sciences Group, Inc. engages in the development and commercialization of immunotherapeutics for cancer indications. Its product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Head office United States
CEO Angelos Stergiou
Employees 15
Founded 2006
Website www.sellaslifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today